[Headlines Only] [Top Stories Only]
Categories
· Health/Science
· Cessation
· Nicotine
· Business (General)

• Nabi closes license deal with GlaxoSmithKline 

Jump to full article: Associated Press (AP), 2010-03-08

Intro:

Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline.

The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments.

Nabi shareholders voted in favor of the deal on Tuesday. The companies announced it in November.

Nabi is developing NicVAx, which is intended to train the immune system to make antibodies that will attach themselves to nicotine.

Jump to full article »